The Life Sciences team advised Nimbus Therapeutics on the closing of a $105 million private financing round which was led by BVF Partners L.P. with participation from existing investors including RA Capital Management and Atlas Venture. Access Biotechnology, Commodore Capital, Logos Capital, Surveyor Capital, and a large alternative asset manager joined as new investors in this financing.

In addition to the Phase 2 studies of Nimbus’ allosteric TYK2 inhibitor, the financing will support a first-in-human study of the company’s HPK1 inhibitor candidate in cancer patients with solid tumors, which will begin later this year, and will accelerate preclinical programs against multiple targets in oncology and immunology. Nimbus expects to initiate IND-enabling studies on two novel agents in 2022.

Nimbus Therapeutics designs breakthrough medicines. Utilizing its powerful structure-based drug discovery engine, Nimbus designs potent and selective small molecule compounds targeting proteins that are known to be fundamental drivers of pathology in highly prevalent human diseases and which have proven difficult for other drug makers to tackle.

The Goodwin team was led by William Collins, Gaby Morales-Rivera, Mitchell Bloom, Brittany Morreale, Karin Yoo, and Pablo Hernandez RomeroDan Karelitz, and Nicole Spiteri, Paul Jin, and Brad Weber.

For additional background on the funding, please read the press release and coverage in FierceBiotech.